Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on October 23, 2014. The report details amendments to executive employment agreements, salary adjustments, and significant equity grants under the Company's 2010 Equity Participation Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The financial data presented is limited to executive compensation adjustments and equity grant valuations.
Material Changes
- CEO Compensation Reduction: Mark Weinreb's annual salary was reduced from $600,000 to $450,000 effective October 1, 2014, and will further decrease to $400,000 effective January 1, 2015. His annual bonus entitlement remains at 50% of his annual salary.
- VP R&D Compensation Increase: Francisco Silva's annual salary will increase from $230,000 to $250,000 effective January 1, 2015. He will also be eligible for an annual bonus of up to 20% of his salary based on future performance standards.
- Equity Plan Expansion: The authorized share count under the 2010 Equity Participation Plan was increased from 12,000,000 to 20,000,000 shares.
Guidance, Outlook, and Unusual Items
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The primary unusual item is the simultaneous reduction of the CEO's base salary and the expansion of the equity pool with significant option grants to executives and directors.
Equity Grants Summary
| Recipient | Shares Granted | Exercise Price |
|---|---|---|
| Mark Weinreb (CEO) | 3,000,000 | $0.33 |
| Francisco Silva (VP R&D) | 750,000 | $0.33 |
| A. Jeffrey Radov | 1,000,000 | $0.33 |
| Joseph Swiader | 500,000 | $0.33 |
| Paul Jude Tonna | 500,000 | $0.33 |
| Mandy Clyde | 200,000 | $0.33 |
| Dr. Wayne Marasco (SAB Chair) | 250,000 | $0.34 |
Investor Verification Checklist
- Verify the dilution impact of the 8,000,000 share increase in the equity plan and the 6,200,000 total options granted.
- Confirm the specific performance standards for Francisco Silva's new bonus structure, as they were not defined in this filing.
- Review the Company's cash position to assess the sustainability of the remaining executive compensation obligations.
- Check subsequent filings for the vesting schedules of the newly granted options.